MARTINELLI, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 988
EU - Europa 201
AS - Asia 97
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.292
Nazione #
US - Stati Uniti d'America 984
SE - Svezia 52
SG - Singapore 43
UA - Ucraina 43
IT - Italia 40
CN - Cina 29
IN - India 24
FI - Finlandia 19
BG - Bulgaria 12
GB - Regno Unito 10
DE - Germania 7
RU - Federazione Russa 7
CA - Canada 4
IE - Irlanda 4
RO - Romania 4
TG - Togo 2
AR - Argentina 1
BE - Belgio 1
EU - Europa 1
FR - Francia 1
GE - Georgia 1
MU - Mauritius 1
NL - Olanda 1
ZA - Sudafrica 1
Totale 1.292
Città #
Fairfield 172
Woodbridge 142
Houston 85
Ashburn 81
Seattle 74
Cambridge 60
Chandler 60
Wilmington 58
Ann Arbor 44
Singapore 33
San Paolo di Civitate 26
Beijing 24
Plano 17
Princeton 17
Santa Clara 16
Millbury 14
Lawrence 13
Jacksonville 12
Sofia 12
Rome 9
Boardman 6
Boston 4
Dublin 4
San Diego 4
Toronto 4
Dearborn 3
Falls Church 3
Andover 2
Bühl 2
Des Moines 2
Falkenstein 2
Kunming 2
Lomé 2
Moscow 2
Norwalk 2
Ambrolauri 1
Auburn Hills 1
Bremen 1
Brescia 1
Brussels 1
Federal 1
Florence 1
Jinan 1
London 1
Muizenberg 1
Nanning 1
New York 1
Nuremberg 1
Philadelphia 1
Redmond 1
Romola 1
San Francisco 1
San Mateo 1
Trento 1
Ürümqi 1
Totale 1.033
Nome #
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes 105
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment 93
NILOTINIB FOR THE FRONTLINE TREATMENT OF PH(+) CHRONIC MYELOID LEUKEMIA. 90
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 87
Treatment of philadelphia-positive chronic myeloid leukemia with imatinib: Importance of a stable molecular response 87
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. 86
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 82
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. 81
A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study 80
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older 75
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) 72
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 62
null 52
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report 51
null 48
null 46
null 46
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients 26
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party 14
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 12
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 10
Totale 1.305
Categoria #
all - tutte 3.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.354


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020228 0 0 0 0 0 34 43 47 40 29 25 10
2020/202183 12 17 5 6 2 6 0 6 12 8 8 1
2021/2022180 1 13 22 6 27 4 4 17 7 19 24 36
2022/2023221 29 55 6 26 27 32 0 9 34 0 2 1
2023/202456 7 16 1 0 2 11 0 1 0 12 4 2
2024/202559 6 2 7 3 28 13 0 0 0 0 0 0
Totale 1.305